ArticleMetabolic brain disease2025
Evaluating the impact of Pomalidomide on memory dysfunction induced by neuroinflammation in Pentylenetetrazole-seizure model of male Wistar rats.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation, a consequence and cause of epileptic seizures, is one of the leading causes of memory dysfunction in epileptic patients. The; current study evaluated Pomalidomide's; (POM) anti-inflammatory effect on passive avoidance memory impairments caused by Pentylenetetrazole-induced seizure in male Wistar rats. Rats were grouped into five groups, including control, Pentylenetetrazole (PTZ), and treatment groups. Three groups were pretreated with different doses of Pomalidomide (25, 50, and 100 mg/kg) before PTZ 70 (mg/kg). The Shuttle box test was utilized to examine passive avoidance memory and learning. Finally, brain samples were prepared under deep anesthesia and used for histological observation and gene expression studies. Based on data analysis Pomalidomide -pretreated groups showed better memory performance than either the control or the PTZ group (P < 0.05). Also, the anti-inflammatory effects of POM caused the expression of Nuclear Factor Kappa B (NF-kB) and Tumor necrosis factor alpha (Tnf-α) in the hippocampus to decrease significantly compared to the control group (P < 0.05). In addition, histological examinations obtained from H&E staining in the hippocampus also showed the protective effects of the Pomalidomide. The results indicated that Pomalidomide reduced the expression of inflammatory mediators in the hippocampus and has a neuroprotective effect. It seems that in this way it reduces memory impairments caused by acute seizure induction.
Indexed as
Identifiers
40358812What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.